We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
MedXY AI/MedXY News/Tag: immunotherapy
MedXY News
EnglishTag

immunotherapy

Ask MedXY AI
type 2 diabetesclinical trialheart failureimmunotherapyobesitycardiovascular riskatrial fibrillationbiomarkerscritical careclinical trialsHypertensionartificial intelligenceCardiologyoncologypublic healthtype 1 diabetesdiabetesMortalityAlzheimer's diseasecardiovascular diseasebreast cancerepidemiology

Latest news

Tag

Pembrolizumab Plus Chemotherapy for Cervical Cancer: Five-Year Exploratory Analysis from the KEYNOTE-826 Randomized Clinical Trial
newschemotherapyKEYNOTE-826

Pembrolizumab Plus Chemotherapy for Cervical Cancer: Five-Year Exploratory Analysis from the KEYNOTE-826 Randomized Clinical Trial

By MedXY|Sep 15, 2026

Five-year data from KEYNOTE-826 confirm pembrolizumab combined with chemotherapy as a durable, first-line treatment improving survival in persistent, recurrent, or metastatic cervical cancer without new safety concerns.

Bicistronic CD19/CD22 CAR T-Cell Therapy: A Breakthrough for Pediatric Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia
Hematology-Oncologypediatric oncology
CAR T-cell therapy

Bicistronic CD19/CD22 CAR T-Cell Therapy: A Breakthrough for Pediatric Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia

By MedXY|Sep 6, 2026

A phase 2 trial shows bicistronic CD19/CD22 CAR T-cell therapy yields high remission rates with durable event-free survival in pediatric relapsed/refractory B-ALL, reducing antigen-negative relapse risks and improving outcomes.

Mezigdomide Reverses T-Cell Exhaustion Through IKZF1/IKZF3 Degradation and Cytokine Pathway Reinvigoration in Multiple Myeloma
Clinical Updatesmultiple myelomaIKZF3

Mezigdomide Reverses T-Cell Exhaustion Through IKZF1/IKZF3 Degradation and Cytokine Pathway Reinvigoration in Multiple Myeloma

By MedXY|Sep 3, 2026

Mezigdomide targets IKZF1/IKZF3 to reverse T-cell exhaustion, enhancing cytokine production and improving T-cell engager efficacy in multiple myeloma, a breakthrough in overcoming immunotherapy resistance.

Dual HLA-Restricted TCR-Engineered T Cells Targeting Cathepsin G: A Novel Approach for Effective AML Eradication
Hematology-Oncologycathepsin-GHLA restriction

Dual HLA-Restricted TCR-Engineered T Cells Targeting Cathepsin G: A Novel Approach for Effective AML Eradication

By MedXY|Aug 25, 2026

This study demonstrates that T cells engineered with a dual HLA-restricted TCR against cathepsin G effectively and safely eradicate AML cells, offering a promising immunotherapy for a broad AML patient population.

Engineering High-Avidity Cathepsin-G-Specific CAR T Cells: A Promising Therapeutic Strategy for Acute Myeloid Leukemia
Hematology-Oncologyacute myeloid leukemiaCAR T cells

Engineering High-Avidity Cathepsin-G-Specific CAR T Cells: A Promising Therapeutic Strategy for Acute Myeloid Leukemia

By MedXY|Aug 23, 2026

This article reviews the development of high-avidity cathepsin-G-specific CAR T cells engineered with enhanced functional features to selectively target acute myeloid leukemia without hematopoietic toxicity, highlighting their preclinical e

Gut Microbiota and Metabolomic Signatures as Predictors of Immunotherapy Outcomes in MASLD and Viral HCC
Gastroenterologygut microbiotametabolomics

Gut Microbiota and Metabolomic Signatures as Predictors of Immunotherapy Outcomes in MASLD and Viral HCC

By MedXY|Aug 22, 2026

Distinct gut microbial profiles but shared metabolomic markers, especially fecal acetate, predict response and survival with combination immunotherapy in metabolic dysfunction-associated and viral hepatitis-related hepatocellular carcinoma.

Metabolic Checkpoint Role of PCK1 Deficiency in Promoting MASH-HCC via 12-HETE-Induced CD8+ T Cell Dysfunction
Gastroenterology12-HETECD8+ T cell dysfunction

Metabolic Checkpoint Role of PCK1 Deficiency in Promoting MASH-HCC via 12-HETE-Induced CD8+ T Cell Dysfunction

By MedXY|Aug 22, 2026

PCK1 deficiency in hepatocytes drives metabolic reprogramming that fosters MASH-HCC progression by inducing CD8+ T cell dysfunction through 12-HETE-p38 signaling, highlighting a metabolic immunotherapy target to enhance anti-PD-1 efficacy.

Durability of β-Cell Function After Cessation of Baricitinib Immunotherapy in New-Onset Type 1 Diabetes
Diabetes & Endocrinologytype 1 diabetesβ-cell function

Durability of β-Cell Function After Cessation of Baricitinib Immunotherapy in New-Onset Type 1 Diabetes

By MedXY|Aug 22, 2026

Baricitinib treatment in recent-onset type 1 diabetes preserves β-cell function during therapy. However, this effect diminishes within a year after stopping treatment, highlighting the need for sustained immunotherapy for lasting benefit.

Low-dose Blinatumomab Therapy in Multidrug-Resistant Rheumatoid Arthritis: A Case Series Analysis
Hematology-OncologyT-cell Engagermultidrug resistance

Low-dose Blinatumomab Therapy in Multidrug-Resistant Rheumatoid Arthritis: A Case Series Analysis

By MedXY|Aug 17, 2026

A case series assessing the safety and efficacy of low-dose blinatumomab in 15 patients with multidrug-resistant rheumatoid arthritis showed synovial B-cell depletion, reduced disease activity, and improved response to previously ineffectiv

Cost-Effectiveness of Perioperative Pembrolizumab in Head and Neck Cancer: Impact of PD-L1 Expression Levels
newsCost-Effectivenessimmunotherapy

Cost-Effectiveness of Perioperative Pembrolizumab in Head and Neck Cancer: Impact of PD-L1 Expression Levels

By MedXY|Aug 11, 2026

The addition of perioperative pembrolizumab to standard care improves event-free survival in locally advanced head and neck squamous cell carcinoma, with cost-effectiveness dependent on PD-L1 combined positive score.

Pembrolizumab Combined with Radiotherapy Shows Promise in Advanced Cutaneous T-Cell Lymphoma: Final Results from UK NCRI Phase II Trial
Hematology-OncologyCutaneous T-Cell LymphomaRadiotherapy

Pembrolizumab Combined with Radiotherapy Shows Promise in Advanced Cutaneous T-Cell Lymphoma: Final Results from UK NCRI Phase II Trial

By MedXY|Aug 10, 2026

The UK NCRI phase II trial demonstrates pembrolizumab with localized radiotherapy yields meaningful response rates and durable control in relapsed/refractory advanced cutaneous T-cell lymphoma, marking an important step in improving outcome

Revolutionizing Classical Hodgkin Lymphoma Treatment: The Promise of Anti-PD-1 Therapy
Hematology-OncologyNivolumabimmunotherapy

Revolutionizing Classical Hodgkin Lymphoma Treatment: The Promise of Anti-PD-1 Therapy

By MedXY|Aug 5, 2026

Anti-PD-1 therapy has transformed classical Hodgkin lymphoma management, demonstrating safety, feasibility, and durable efficacy across treatment settings—from relapsed/refractory disease to frontline therapy.

Multimodal C9-66 CAR-T Cell Therapy: A Promising Advance in Pancreatic Cancer Treatment
newsCAR-T Therapyimmunotherapy

Multimodal C9-66 CAR-T Cell Therapy: A Promising Advance in Pancreatic Cancer Treatment

By MedXY|Jul 16, 2026

This article reviews the development and preclinical evaluation of C9-66 CAR-T cell therapy targeting oncofetal chondroitin sulfate in pancreatic cancer, highlighting metabolic and microenvironmental optimizations that improve efficacy and

Distinct Immune Subtypes in Type 1 Diabetes: Implications for Disease Progression and Personalized Immunotherapy
Allergy & ImmunologyDisease ProgressionImmune Subtypes

Distinct Immune Subtypes in Type 1 Diabetes: Implications for Disease Progression and Personalized Immunotherapy

By MedXY|Jul 14, 2026

Two immunologically distinct, age-independent subtypes of new-onset type 1 diabetes demonstrate differing progression rates and therapeutic responses, offering a path toward tailored immunotherapies.

Evaluating Consolidative Thoracic Radiotherapy with Atezolizumab Maintenance in Extensive-Stage Small Cell Lung Cancer: Insights from the Phase 2 TREASURE Trial
newsatezolizumabclinical trial

Evaluating Consolidative Thoracic Radiotherapy with Atezolizumab Maintenance in Extensive-Stage Small Cell Lung Cancer: Insights from the Phase 2 TREASURE Trial

By MedXY|Jul 14, 2026

The Phase 2 TREASURE trial investigated the safety and efficacy of adding consolidative thoracic radiotherapy to atezolizumab maintenance in extensive-stage small cell lung cancer, revealing increased toxicity without survival benefit, unde

CD7-Directed CAR-T Cell Therapy in Relapsed/Refractory CD7-Positive Acute Myeloid Leukemia: Clinical Advances and Future Perspectives
Clinical Updatesacute myeloid leukemiaCD7 CAR-T

CD7-Directed CAR-T Cell Therapy in Relapsed/Refractory CD7-Positive Acute Myeloid Leukemia: Clinical Advances and Future Perspectives

By MedXY|Jul 13, 2026

This review synthesizes recent phase I trial data on CD7 CAR-T therapies in relapsed/refractory AML, highlighting promising safety, high response rates, challenges with antigen loss relapse, and avenues for future research.

Durvalumab Plus Chemotherapy Extends Survival in Advanced Biliary Tract Cancer: Insights from the TOPAZ-1 Trial Four-Year Post Hoc Analysis
GastroenterologyBiliary tract cancercisplatin

Durvalumab Plus Chemotherapy Extends Survival in Advanced Biliary Tract Cancer: Insights from the TOPAZ-1 Trial Four-Year Post Hoc Analysis

By MedXY|Jul 12, 2026

A four-year post hoc analysis of the TOPAZ-1 trial confirms that durvalumab combined with gemcitabine and cisplatin offers a long-term survival benefit with manageable safety as first-line treatment for advanced biliary tract cancer.

Strategic Sequencing of Systemic Therapies in Advanced Hepatocellular Carcinoma: Beyond the Second Line
GastroenterologyChất ức chế kinase tyrosinehepatocellular carcinoma

Strategic Sequencing of Systemic Therapies in Advanced Hepatocellular Carcinoma: Beyond the Second Line

By MedXY|Jun 28, 2026

This article reviews evolving therapeutic sequences in advanced hepatocellular carcinoma, highlighting the integration of immune-based combinations, tyrosine kinase inhibitors, liver function preservation, and the emerging multidimensional

Targeting NEK9 to Overcome Immunotherapy Resistance in Hepatocellular Carcinoma by Reprogramming the Tumor Microenvironment
Gastroenterologyhepatocellular carcinomaimmunotherapy

Targeting NEK9 to Overcome Immunotherapy Resistance in Hepatocellular Carcinoma by Reprogramming the Tumor Microenvironment

By MedXY|Jun 27, 2026

NEK9 upregulation in hepatocellular carcinoma promotes immune evasion by enhancing PD-L1 expression and recruiting suppressive myeloid cells. Novel NEK9 inhibitors synergize with PD-L1 blockade, remodeling the tumor microenvironment and imp

Immune Checkpoint Inhibitors Deliver Durable Responses in MSI-H Gastroesophageal Adenocarcinoma
GastroenterologydMMRgastroesophageal adenocarcinoma

Immune Checkpoint Inhibitors Deliver Durable Responses in MSI-H Gastroesophageal Adenocarcinoma

By MedXY|Jun 19, 2026

MSI-H/dMMR gastroesophageal adenocarcinoma showed high response rates to immune checkpoint inhibitors, including durable complete responses in locoregional disease that may support carefully selected nonoperative management.

1 / 9
123…9
Next
Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities